The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised Tuesday to examine lowering their prices in the United States, after ...
格隆汇9月25日|丹麦制药巨头 诺和诺德 ( 125.44, 1.74, 1.41%) CEO Lars Jorgensen在美国国会参议院接受了质询,参议员认为,诺和诺德旗下减肥药物Wegovy和糖尿病药物Ozempic在美国的定价过高,明显高于它们在欧洲地区的售价。参议院卫生、教育、劳工和养老金委员会主席桑德斯援引数据称,诺和诺德今年已通过Wegovy和Ozempic获得了近500亿美元的收入 ...